Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 10,628 matching trials from the live ClinicalTrials.gov search.

Filters: Pittsburgh, Pennsylvania Clear all

Conditions: Brain and Central Nervous System Tumors
Interventions: carboplatin, cereport, radiation therapy; Drug · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 21 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 19
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 15 more

Conditions: Non-Hodgkin's Lymphoma
Interventions: Bortezomib + Rituximab, Rituximab; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 676 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 41
States / cities: Opelika, Alabama • Alhambra, California • Bakersfield, California + 36 more

Conditions: Morbid Obesity, Metabolic Disease
Interventions: Laparoscopic Roux-en-Y Gastric Bypass; Procedure
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 10
States / cities: Irvine, California • Orange, California • Atlanta, Georgia + 6 more

Conditions: Stroke, Spinal Cord Injuries
Interventions: Rehabilitation using motorized glove for stroke and spinal cord injury, Functional MRI for stroke and spinal cord injury, Transcranial magnetic stimulation (TMS) for stroke and spinal cord injury; Other
Lead sponsor: VA Pittsburgh Healthcare System; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Rheumatoid Arthritis
Interventions: Sarilumab, Etanercept, Methotrexate, Placebo (for sarilumab), Placebo (for etanercept), Adalimumab; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 776 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 30
States / cities: Birmingham, Alabama • Glendale, California • Thousand Oaks, California + 27 more

Conditions: Metatarsus Adductus, Hallux Valgus
Interventions: Treatment of metatarsus adductus and hallux valgus with the Adductoplasty™ Procedure in combination with the Lapiplasty® Procedure; Device
Lead sponsor: Treace Medical Concepts, Inc.; Industry
Eligibility: 14 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2030
U.S. locations: 9
States / cities: Greeley, Colorado • Ankeny, Iowa • Yarmouth, Maine + 6 more

Conditions: Benign Right Colon Disease, Malignant Right Colon Disease
Interventions: Right Colectomy with Intracorporeal Anastomosis, Right Colectomy with Extracorporeal Anastomosis; Procedure
Lead sponsor: Intuitive Surgical; Industry
Eligibility: 18 Years and older
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 4
States / cities: Irvine, California • Ann Arbor, Michigan • St Louis, Missouri + 1 more

Conditions: Hemodialysis, Hypotension, Circulatory Stress, Photo-plethysmography
Interventions: Not listed
Lead sponsor: West Penn Allegheny Health System; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Head and Neck Cancer, Precancerous Condition
Interventions: cetuximab; Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 9
States / cities: San Francisco, California • Chicago, Illinois • Lexington, Kentucky + 5 more

Conditions: Bladder Cancer, Quality of Life
Interventions: provider monitoring and feedback to remote data, participant monitoring of remote data; Device
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Non-small Cell Lung Cancer
Interventions: Dacomitinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 12
States / cities: Beverly Hills, California • Los Angeles, California • Washington D.C., District of Columbia + 3 more

Conditions: Muscular Dystrophy, Duchenne
Interventions: Pentoxifylline; Drug
Lead sponsor: Cooperative International Neuromuscular Research Group; Network
Eligibility: 7 Years and older · Male only
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 5
States / cities: Washington D.C., District of Columbia • Rochester, Minnesota • St Louis, Missouri + 2 more

Conditions: Pneumococcal Disease
Interventions: PG4, 20-valent pneumococcal conjugate vaccine (20vPnC); Biological
Lead sponsor: Pfizer; Industry
Eligibility: 42 Days to 211 Days
Enrollment: 3,230 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 111
States / cities: Bessemer, Alabama • Birmingham, Alabama • Fayetteville, Arkansas + 74 more

Conditions: Deep Vein Thrombosis, Venous Thrombosis, Postphlebitic Syndrome, Venous Thromboembolism, Post Thrombotic Syndrome
Interventions: Recombinant tissue plasminogen activator (rt-PA); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 16 Years to 75 Years
Enrollment: 692 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 56
States / cities: Glendale, Arizona • Orange, California • Stanford, California + 48 more

Conditions: EBV-Related Post-Transplant Lymphoproliferative Disorder, Monomorphic Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder, Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder, Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder, Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder
Interventions: Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes, Rituximab; Biological
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 29 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 38
States / cities: Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 34 more

Conditions: Anesthesia, Pain, Amnesia
Interventions: Sevoflurane, Peripheral Nerve Stimulation; Drug · Device
Lead sponsor: Keith M Vogt; Other
Eligibility: 18 Years to 59 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Gait, Medication Induced Gait Disturbances
Interventions: BioButton Device, Providing Clinical Care with BioButton Device; Device
Lead sponsor: Charles Lin; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Depression, Major Depressive Disorder
Interventions: Naltrexone 50 Mg Oral Tablet, Placebo oral tablet; Drug
Lead sponsor: Marta Peciña, MD PhD; Other
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Opioid-Induced Respiratory Depression, Postoperative Complications (Cardiopulmonary), Respiratory Complications Due to Anesthesia
Interventions: Infrared Pupillometry; Device
Lead sponsor: NeurOptics Inc; Industry
Eligibility: 3 Years to 17 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: San Francisco, California • Pittsburgh, Pennsylvania

Conditions: HIV
Interventions: DV201P-RNA, DV202B1-RNA; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 7
States / cities: Atlanta, Georgia • Decatur, Georgia • Boston, Massachusetts + 4 more

Conditions: Colorectal Cancer, Fatigue, Long-term Effects Secondary to Cancer Therapy in Adults, Pain, Psychosocial Effects of Cancer and Its Treatment
Interventions: Telephone interview; Other
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: Not listed
Enrollment: 744 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 200
States / cities: Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 132 more

Conditions: Acute Otitis Media
Interventions: cefdinir; Drug
Lead sponsor: Abbott; Industry
Eligibility: 6 Months to 4 Years
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 13
States / cities: Scottsdale, Arizona • Clovis, California • Dinuba, California + 9 more

Conditions: Infection
Interventions: Ibuprofen, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 5
States / cities: Cypress, California • Westlake Village, California • Omaha, Nebraska + 2 more

Conditions: Advanced Melanoma, Unresectable Melanoma
Interventions: Nivolumab, Axitinib; Drug
Lead sponsor: Yana Najjar; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

Radiation Therapy Plus Carboplatin and Lobradimil in Treating Children With Newly Diagnosed Brain Stem Gliomas

Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Study Evaluating Metabolic Syndrome in Subjects Undergoing Gastric Bypass Bariatric Syndrome

Cortical Biomarkers of Hand Function and Recovery After Injury

An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate

Outcomes Following Combined Adductoplasty™ and Lapiplasty® (MTA3D)

Robotic-assisted and Laparoscopic Right Colectomy Study - Intracorporeal vs. Extracorporeal Anastomoses

Measuring Cardiovascular Stress in Patients on Hemodialysis

Cetuximab in Treating Patients With Precancerous Lesions of the Upper Aerodigestive Tract

The Use of Remote Monitoring to Improve Patient-Reported Outcomes and Readmission Rates Following Radical Cystectomy

A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer

Study of Daily Pentoxifylline as a Rescue Treatment in Duchenne Muscular Dystrophy

A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder

Sevoflurane's Effect on Neurocognition Study

BioButton Among Nursing Home Residents

Study of Naltrexone-Induced Blockade of Antidepressant Effects

Pupillometry in Identifying Risk of Postoperative Opioid-induced Respiratory Depression in Children Undergoing Tonsillectomy

Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA in Adult Participants Without HIV

Patient-Reported Outcomes in Long-Term Survivors of Colon and Rectal Cancers

Safety and Efficacy Study of Cefdinir Oral Suspension, in Pediatric Subjects to Treat Acute Otitis Media

Study Evaluating The Efficacy Of A Novel Ibuprofen Formulation On Fever In Patients With An Uncomplicated Acute Infection

Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma